MetaCap

Ginkgo Bioworks (DNA) vs Valneva (VALN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Ginkgo Bioworks (DNA) has outperformed Valneva (VALN) over the past year, losing 8.7% versus a loss of 40.1%. Over five years, VALN leads with a -91.3% price change compared with -98.5% for DNA. Valneva is the larger company by market cap ($490.9 million vs $483.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DNA-8.69%VALN-40.14%
+90%+19%-51%
Nov 21, 20251 yearNov 20, 2026
DNA-98.61%VALN-89.45%
+31%-37%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DNA versus VALN key metrics
MetricDNAVALN
Share price$7.46$5.16
Market cap$483.54M$490.86M
1-day change-9.02%-3.82%
YTD return-10.23%-41.50%
1-year return-8.69%-40.14%
5-year return-98.45%-91.34%
Forward P/E—4.34
EPS (TTM)$-4.24$-2.10
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$170.16M—
Revenue growth (YoY)-25.06%—
Net income (latest FY)$-312.76M—
Operating margin-185.29%—
Net margin-183.81%—
52-week high$18.22$12.18
52-week low$5.37$4.75
Distance from 52-week high-59.06%-57.64%
Analyst consensusunderperformnone
Avg. price target upside+7.24%+137.98%
Average volume2.53M23.10K
Shares outstanding53.94M95.13M
Employees485620
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DNA has outperformed VALN by 31.4 percentage points over the past year.

About Ginkgo Bioworks

DNA stock →

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 485 employees

About Valneva

VALN stock →

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 620 employees

DNA vs VALN FAQ

Which is bigger, Ginkgo Bioworks or Valneva?

Valneva (VALN) is larger, with a market capitalization of $490.86M compared with $483.54M for Ginkgo Bioworks (DNA).

Which stock has performed better over the past year, DNA or VALN?

DNA returned -8.69% over the past 12 months, compared with -40.14% for VALN (price return, excluding dividends). Past performance does not predict future results.

Are Ginkgo Bioworks and Valneva in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons